Status:
COMPLETED
"Association of Proteinuria and Progression of Kidney Dysfunction in Sickle Cell Disease"Disease
Lead Sponsor:
Soutien aux Actions contre les Maladies du Globule Rouge
Collaborating Sponsors:
Novartis
Conditions:
Change in Albumin to Creatinine Ratio and Glomerular Filtration Rate
Progression of Kidney Failure and or All-cause Mortality
Eligibility:
All Genders
18+ years
Brief Summary
To describe change in ACR and eGFR during study follow-up, and assesss the association of baseline and change in ACR and eGFR, with progression of kidney failure and/or all-cause mortality.
Detailed Description
This is a retrospective, non-interventional, secondary use of the data coming from the single-center secondary GEN-MOD study cohort at the Henri Mondor Hospital (Creteil, France). The GEN-MOD cohort i...
Eligibility Criteria
Inclusion
- Adults aged ≥ 18 years old.
- Confirmed diagnosis of SCD by Hb electrophoresis or high performance liquid chromatography. SCD genotypes HbSS, HbSβ0-thal.
- Availability of ACR and eGFR baseline records.
Exclusion
- Patients enrolled in a chronic transfusion program.
- Patients receiving hydroxyurea treatment at the time of study enrollment.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
355 Patients enrolled
Trial Details
Trial ID
NCT05407740
Start Date
March 1 2021
End Date
December 1 2021
Last Update
May 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henri Mondor Hospital
Créteil, France, 94000